Page 171 - Haematologica - Vol. 105 n. 6 - June 2020

IGHV and outcome in CLL: a population-based study
imab treatment achieves long-term disease- free survival in IGHV-mutated chronic lym- phocytic leukemia. Blood. 2016;127(3):303- 309.
17. Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remis- sion after first-line fludarabine-cyclophos- phamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921-1924.
18. Lin KI, Tam CS, Keating MJ, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and ritux- imab (FCR) or related chemoimmunothera- py regimens. Blood. 2009;113(14):3168- 3171.
19. da Cunha-Bang C, Geisler CH, Enggaard L, et al. The Danish National Chronic Lymphocytic Leukemia Registry. Clin Epidemiol. 2016;8:561-565.
20. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7 Suppl):22-25.
21. Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014; 29(8):541-549.
22. Shanafelt TD, Wang V, Kay NE, et al. A Randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard flu- darabine, cyclophosphamide, and ritux- imab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912). Blood. 2018;132(Suppl 1):LBA-4- LBA-4.
23. Lepretre S, Aurran T, Mahe B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012;119(22):5104-5110.
24. Munir T, Howard DR, McParland L, et al. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia. 2017;31(10):2085-2093.
25. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoim- munotherapy in older patients with untreated CLL. N Engl J Med. 2018;379 (26):2517-2528.
26. Sylvan SE, Asklid A, Johansson H, et al. First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real- world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica. 2019;104(4):797-804.
27. Robak T, Burger JA, Tedeschi A, et al. Single-agent ibrutinib versus chemoim- munotherapy regimens for treatment-naive
patients with chronic lymphocytic 40.
leukemia: a cross-trial comparison of phase 3 studies. Am J Hematol. 2018;93(11):1402- 1410.
28. O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocyt- ic leukemia: a 5-year experience. Blood. 2018;131(17):1910-1919.
29. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting condi- tions. N Engl J Med. 2014;370(12):1101- 1110.
30. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a ran- domised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873-1883.
31. Goede V, Fischer K, Dyer MJ, et al. Overall survival benefit of obinutuzumab over rit- uximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. EHA Learning Center, 2018; 215923.S151.
32. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlo- rambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56.
33. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
34. Laurenti L, Innocenti I, Autore F, et al. Bendamustine in combination with ritux- imab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: a retrospective analysis of real- life practice in Italian hematology depart- ments. Leuk Res. 2015;39(10):1066-1070.
35. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with ritux- imab for previously untreated patients with chronic lymphocytic leukemia: a multicen- ter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209-3216.
36. Jain P, Nogueras Gonzalez GM, Kanagal- Shamanna R, et al. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic
37. Al-Sawaf O, Bahlo J, Robrecht S, et al. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018;183(5):727-735.
38. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236.
39. Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treat- ment of CLL. N Engl J Med. 2019;380(22): 2095-2103.
40. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Under- representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-2067.
41. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21(7):1383-1389.
42. Goede V, Cramer P, Busch R, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99(6):1095-1100.
43. Wieringa A, Boslooper K, Hoogendoorn M, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lym- phoma treated with R-CHOP: a popula- tion-based cohort study. Br J Haematol. 2014;165(4):489-496.
44. Zhao H, Wang T, Wang Y, et al. Comorbidity as an independent prognostic factor in elderly patients with peripheral T- cell lymphoma. Onco Targets Ther. 2016;9:1795-1799.
45. Foster MC, Coresh J, Hsu CY, et al. Serum beta-trace protein and beta2-microglobulin as predictors of ESRD, mortality, and car- diovascular disease in adults with CKD in the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis. 2016; 68(1):68-76.
46. Delgado J, Pratt G, Phillips N, et al. Beta2- microglobulin is a better predictor of treat- ment-free survival in patients with chronic lymphocytic leukaemia if adjusted accord- ing to glomerular filtration rate. Br J Haematol. 2009;145(6):801-805.
47. Rostgaard K, Vaeth M, Rootzen H, et al. Do changes in lymph node status distribution explain trends in survival of breast cancer patients in Denmark? Eur J Cancer Prev. 2006;15(5):398-404.
lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol. 2018;180(1):33-
haematologica | 2020; 105(6)
1629